Robenacoxib in the dog: Target species safety in relation to extent and duration of inhibition of COX-1 and COX-2

Journal of Veterinary Pharmacology and Therapeutics

Volumn 34, Issue 3, 2011, Pages 298-311

  King, Jonathan N ^a   Arnaud, J P ^b   Goldenthal, E I ^c   Gruet, P ^d   Jung, M ^e   Seewald, W ^a   Lees, P ^f  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Avogadro Parc de Génibrat ^*  (France)

^c MPI RESEARCH   (United States)

^d Novartis Sante Animale SAS   (France)

^e Novartis Centre de Recherches   (Switzerland)

^f ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PLACEBO; ROBENACOXIB;

ANIMAL EXPERIMENT; ARTICLE; AUTOPSY; BLEEDING TIME; CLINICAL CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DRUG SAFETY; DRUG SELECTIVITY; ELECTROCARDIOGRAPHY; ENZYME INHIBITION; FEMALE; JOINT STIFFNESS; MALE; MEAN RESIDENCE TIME; NONHUMAN; OPHTHALMOSCOPY; PHARMACODYNAMICS; PRIORITY JOURNAL; TOXICOKINETICS; URINALYSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DIPHENYLAMINE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTRIC MUCOSA; INTESTINAL MUCOSA; KIDNEY; LIVER; MALE; PHENYLACETATES; TABLETS;

CANIS FAMILIARIS;

EID: 78651298664     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2010.01209.x     Document Type: Article

References (26)

1. Baraf, H.S.B., Fuentealba, C., Greenwald, M., Brzezicki, J., O'Brien, K., Soffer, B., Bird, S., Kaur, A. & Curtis, S.P. (2007) Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the etoricoxib versus diclofenac sodium gastrointestinal tolerability and effectiveness (EDGE) trial. Journal of Rheumatology, 34, 408-420.
2. Bergh, M.S. & Budsberg, S.C. (2005) The coxib NSAIDs: potential clinical and pharmacologic importance in veterinary medicine. Journal of Veterinary Internal Medicine, 19, 633-643.
3. Boelsterli, U.A. (2003) Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicology & Applied Pharmacology, 192, 307-322.
4. Brune, K. & Furst, D.E. (2007) Combining enzyme selectivity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability. Rheumatology, 46, 911-919.
5. Brune, K. & Hinz, B. (2004) Selective cyclooxygenase-2 inhibitors: similarities and differences. Scandinavian Journal of Rheumatology, 33, 1-6.
6. Cheng, H.F. & Harris, R.C. (2004) Cyclooxygenases, the kidney, and hypertension. Hypertension, 43, 525-530.
7. Flower, R.J. (2003) The development of COX2 inhibitors. Nature Reviews Drug Discovery, 2, 179-191.
8. Giraudel, J.M., King, J.N., Jeunesse, E.C., Lees, P. & Toutain, P.L. (2009a) Use of a pharmacokinetic/pharmacodynamic approach in the cat to determine a dosage regimen for the COX-2 selective drug robenacoxib. Journal of Veterinary Pharmacology and Therapeutics, 32, 18-30.
9. Giraudel, J.M., Toutain, P.L., King, J.N. & Lees, P. (2009b) Differential inhibition of cyclooxygenase isoenzymes in the cat by the NSAID robenacoxib. Journal of Veterinary Pharmacology and Therapeutics, 32, 31-40.
10. Goodman, L., Torres, B., Punke, J., Reynolds, L., Speas, A., Ellis, A. & Budsberg, S. (2009) Effects of firocoxib and tepoxalin on healing in a canine gastric mucosal injury model. Journal of Veterinary Internal Medicine, 23, 56-62.
11. Halter, F., Tarnawksi, A.S., Schmassmann, A. & Peskar, B.M. (2001) Cyclooxygenase 2 - implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut, 49, 443-453.
12. Jung, M., Lees, P., Seewald, W. & King, J.N. (2009) Analytical determination and pharmacokinetics of robenacoxib in the dog. Journal of Veterinary Pharmacology and Therapeutics, 32, 41-48.
13. King, J.N., Dawson, J., Esser, R.E., Fujimoto, R., Kimble, E.F., Maniara, W., Marshall, P.J., O'Byrne, L., Quadros, E., Toutain, P.L. & Lees, P. (2009) Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2. Journal of Veterinary Pharmacology and Therapeutics, 32, 1-17.
14. King, J.N., Rudaz, C., Borer, L., Jung, M., Seewald, W. & Lees, P. (2010) In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. Research in Veterinary Science, 88, 497-506.
15. Lees, P., Landoni, M.F., Giraudel, J. & Toutain, P.L. (2004) Pharmacodynamics and pharmacokinetics of non-steroidal anti-inflammatory drugs in species of veterinary interest. Journal of Veterinary Pharmacology and Therapeutics, 27, 479-490.
16. Lichtenberger, L.M., Dial, E.J., Romero, J.J., Lechago, J., Jarboe, L.A. & Wolfe, M.M. (1995) Role of luminal ammonia in the development of gastropathy and hypergastrinemia in the rat. Gastroenterology, 108, 320-329.
17. Luna, S.P.L., Basilio, A.C., Steagall, P.V.M., Machado, L.P., Moutinho, F.Q., Takahira, R.K. & Brandao, C.V.S. (2007) Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. American Journal of Veterinary Research, 68, 258-264.
18. MacPhail, C.M., Lappin, M.R., Meyer, D.J., Smith, S.G., Webster, C.R. & Armstrong, P.J. (1998) Hepatocellular toxicosis associated with administration of carprofen in 21 dogs. Journal of the American Veterinary Medical Association, 212, 1895-1901.
19. Moreau, M., Daminet, S., Martel-Pelletier, J., Fernandes, J. & Pelletier, J.P. (2005) Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs. Journal of Veterinary Pharmacology and Therapeutics, 28, 81-86.
20. Reymond, N., Speranza, C., Gruet, P., Seewald, W. & King, J.N. (2010) Robenacoxib versus carprofen for the treatment of canine osteoarthritis; a randomized, non-inferiority field study. Journal of Veterinary Pharmacology and Therapeutics, submitted for publication.
21. Roberts, E.S., Van Lare, K.A., Marable, B.R. & Salminen, W.F. (2009) Safety and tolerability of 3-week and 6-month dosing of Deramaxx (deracoxib) chewable tablets in dogs. Journal of Veterinary Pharmacology and Therapeutics, 32, 329-337.
22. Schnitzer, T., Burmester, G., Mysler, E., Hochberg, M., Doherty, M., Ehrsam, E., Gitton, X., Krammer, G., Mellein, B., Matchaba, P., Gimona, A. & Hawkey, C. on behalf of the TARGET Study Group (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet, 364, 665-674.
23. Smale, S. & Bjarnason, I. (2003) Determining small bowel integrity following drug treatment. British Journal of Clinical Pharmacology, 56, 284-291.
24. Steagall, P.V.M., Mantovani, F.B., Ferreira, T.H., Salcedo, E.S., Moutinho, F.Q. & Luna, S.P.L. (2007) Evaluation of the adverse effects of oral firocoxib in healthy dogs. Journal of Veterinary Pharmacology and Therapeutics, 30, 218-223.
25. Wallace, J.L., McKnight, W., Reuter, B.K. & Vergnolle, N. (2000) NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology, 119, 706-714.
26. Warner, T.D., Giuliano, F., Vojnovi, I., Bukasa, A., Mitchell, J.A. & Vane, J.R. (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proceedings of the National Academy of Science of the United States of America, 96, 7563-7568.